Lilly targets quarterly deals worth up to $5bn to boost R&DEli Lilly is targeting a deal worth between $1 billion to $5 billion every quarter in 2020 as Share XLilly targets quarterly deals worth up to $5bn to boost R&Dhttps://pharmaphorum.com/news/lilly-targets-quarterly-deals-worth-up-to-5bn-boost-rd/
Almirall strikes option deal to buy Bioniz and dermatology drug BNZ-1Almirall has begun an option agreement with California’s Bioniz, which could see it buy the entire company and Share XAlmirall strikes option deal to buy Bioniz and dermatology drug BNZ-1https://pharmaphorum.com/news/almirall-strikes-option-deal-to-buy-bioniz-and-dermatology-drug-bnz-1/
DNA sequencers Illumina and PacBio call off $1.2bn mergerCalifornia-based DNA sequencing firms Illumina and Pacific Biosciences have called off their proposed $1.2 billion merger, after deciding Share XDNA sequencers Illumina and PacBio call off $1.2bn mergerhttps://pharmaphorum.com/news/dna-sequencers-illumina-and-pacific-call-off-1-2-bn-merger/
Roche snaps up ex-US rights to Sarepta’s DMD gene therapyRoche has bought ex-US rights to Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy in a potential multi-billion dollar Share XRoche snaps up ex-US rights to Sarepta’s DMD gene therapyhttps://pharmaphorum.com/news/roche-snaps-up-ex-us-rights-to-sareptas-dmd-gene-therapy/
2019: the year of the pharma mega-merger2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year Share X2019: the year of the pharma mega-mergerhttps://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/
BMS files first drug from triple bet with Celgene shareholders with FDABristol-Myers Squibb has filed the first of three key drugs with the FDA, part of a triple “bet” Share XBMS files first drug from triple bet with Celgene shareholders with FDAhttps://pharmaphorum.com/news/bms-files-first-drug-from-triple-bet-with-celgene-shareholders-with-fda/
Could Spark Therapeutics’ merger with Roche finally get the go-ahead?Spark Therapeutics’ merger with Roche has moved a step closer after the UK’s competition watchdog okayed the $4.8 Share XCould Spark Therapeutics’ merger with Roche finally get the go-ahead?https://pharmaphorum.com/news/could-spark-therapeutics-merger-with-roche-finally-get-the-go-ahead/
Merck buys ArQule and BTK drug for $2.7bnMerck & Co. has announced it is to snap up ArQule for $2.7 billion, just as the US Share XMerck buys ArQule and BTK drug for $2.7bnhttps://pharmaphorum.com/news/merck-buys-arqule-for/
Nine for 2019: how did we do on our predictions, and what does this mean for 2020?Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead. At Share XNine for 2019: how did we do on our predictions, and what does this mean for 2020?https://pharmaphorum.com/views-and-analysis/nine-for-2019-2020/
